Tvardi Therapeutics, Inc.

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and Terms of Use.

HOUSTON--( BUSINESS WIRE )--Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrotic diseases, chronic inflammatory diseases and diverse cancers, today announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics, was selected to make a presentation and co-lead a panel discussion at the 8 th Annual IPF Summit being held in Boston, MA on August 22, 2024. Presentation Title: Unveiling TTI-101 as a Novel Approach in Pulmonary Fibrosis & Interstitial Lung Disease Treatment Session: Examining the Future Directions of the Pulmonary Fibrosis Landscape to Bring Better Drugs to Patients Faster Date & Time: Thursday, August 22, 2024, at 3:45 PM ET Panel Discussion Title: Unravelling the Rationale Behind Combination Therapy & Critical Design & Development Considerations for Emerging Therapeutic Candidates Session: Looking Beyond Monotherapy & The Current Standard of Care to Combining Existing & Emerging Therapeutics for a Combination Approach Date & Time: Thursday, August 22, 2024, at 10:00 AM ET The IPF Summit is the largest drug development initiative for the pulmonary fibrosis community, bringing together key biopharmaceutical companies, clinicians, and academic researchers from around the globe. For more information about the IPF Summit, please visit ipf-summit.com . About Tvardi Therapeutics Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein that plays a central role in the pathogenesis of many fibrotic and inflammatory diseases. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: idiopathic pulmonary fibrosis ( NCT05671835 ) and hepatocellular carcinoma ( NCT05440708 ). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter) .

HOUSTON--( BUSINESS WIRE )--Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET. In addition to the fireside chat, the management team will hold one-on-one investor meetings Monday and Tuesday, August 5-6, 2024. If you are interested in meeting with the Tvardi Therapeutics management team during the conference, please reach out to BTIG . About Tvardi Therapeutics Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: hepatocellular carcinoma ( NCT05440708 ) and idiopathic pulmonary fibrosis ( NCT05671835 ). To learn more, please visit tvardi.com or follow us on LinkedIn and X (Twitter) .